Journal of Histochemistry and Cytochemistry, Vol. 51, 297-302, March 2003, Copyright © 2003, The Histochemical Society, Inc.


ARTICLE

NAD(P)H:Quinone Oxidoreductase 1 Expression in Kidney Podocytes

Francesco Zappaa, Timothy Warda, Ennio Pedrinisb, John Butlera, and Alan McGowna
a CRC Department of Drug Development, Paterson Institute for Cancer Research and Christie Hospital NHS Trust, Manchester, United Kingdom
b Institute of Pathology of Southern Switzerland, Locarno, Switzerland

Correspondence to: Francesco Zappa, Dept. of Medical Oncology, Institute of Oncology of Southern Switzerland (IOSI), 6500 Bellinzona-TI, Switzerland. E-mail: fzappa@ticino.com


  Summary
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

NAD(P)H:quinone oxidoreductase 1 (NQO1; DT-diaphorase; DTD) is a cytosolic two-electron reductase, and compounds of the quinone family such as mitomycin C are efficiently bioactivated by this enzyme. The observation that DT-diaphorase is highly expressed in many cancerous tissues compared to normal tissues has provided us with a potentially selective target that can be exploited in the design of novel anticancer agents. Because of the relative lack of information about the cell-specific expression of DT-diaphorase, the purpose of this study was to map the distribution of this enzyme in normal human tissues. Fifteen tissue samples from normal human kidney were analyzed for expression of DT-diaphorase by immunohistochemistry (two-step indirect method). We found a specific high expression of DT-diaphorase in glomerular visceral epithelial cells (podocytes). These results suggest that a high expression of DT-diaphorase in podocytes could play a major role in the pathogenesis of renal toxicity and mitomycin C-induced hemolytic uremic syndrome, in which injury to the glomerular filtration mechanism is the primary damage, leading to a cascade of deleterious events including microangiopathic hemolytic anemia and thrombocytopenia. This observation has potential therapeutic implications because the DT-diaphorase metabolic pathway is influenced by many agents, including drugs, diet, and environmental cell factors such as pH and oxygen tension.

(J Histochem Cytochem 51:297–302, 2003)

Key Words: DT-diaphorase, NQO1, kidney glomerulus drug effects, immunohistochemistry, P450-reductase


  Introduction
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

MITOMYCIN C (MMC) is an antitumor antibiotic of the quinone family, isolated in 1958 from Streptomyces caespitosus (Wakaki et al. 1958 ), and is used in the treatment of gastrointestinal, lung, head and neck, and breast cancer. This prodrug is the prototype bioreductive alkylating agent and its activation involves the reduction of the quinone group leading to interstrand DNA crosslink formation and cell death (Sartorelli 1986 ; Workman and Stratford 1993 ). A major pathway resulting in MMC activation is catalyzed by the enzyme DT-diaphorase (NAD(P)H:quinone oxidoreductase 1; NQO1; DTD), a cytosolic two-electron reductase ubiquitously expressed (Siegel et al. 1990 ; Ross et al. 1993 , Ross et al. 1994 ; Workman 1994 ) that is known to catalyze the biotransformation of many xenobiotics, including some that are carcinogens (phase II detoxification processes) and some that are antineoplastic agents (bioactivation processes) (Lind et al. 1982 ; Chesis et al. 1984 ). However, a second pathway catalyzed by the one-electron NADPH-dependent cytochrome P450 reductase has been described in individuals with no DTD activity because of a point mutation in the NQO1 gene, leading to minor antitumor efficacy and to the production of toxic semiquinone intermediates (Plumb and Workman 1994 ; Niedermeyer et al. 1999 ).

DT-diaphorase-rich cells are therefore more sensitive to MMC (Lee et al. 1993 ; Saeki et al. 1995 ; Mikami et al. 1996 ). A high expression of this enzyme has been demonstrated in many cancerous tissues compared to normal tissues (Cresteil and Jaiswal 1991 ; Malkinson et al. 1992 ; Belinsky and Jaiswal 1993 ; Smitskamp-Wilms et al. 1995 ). This allows the generation of high concentrations of reactive compounds specifically at the tumor site by the generation of DTD-activated prodrugs (Beall et al. 1995 ), decreasing the risk for toxicity to normal cells. Because reaction with DNA appears to be the primary event leading to cell death, these compounds are most toxic towards rapidly dividing cells. In standard doses, MMC-related common toxicities are nausea, vomiting, myelosuppression, and alopecia. In addition, MMC can cause renal toxicity (Hanna et al. 1981 ; Cantrell et al. 1985 ; Lesesne et al. 1989 ). Nephrotoxicity induced by MMC was first reported in 1971 (Liu et al. 1971 ). It has been described in up to 10% of patients treated with MMC, and is total-dose-dependent (Valavaara and Nordman 1985 ; Verwey et al. 1987 ).

Although there are increasing numbers of reports of MMC-associated renal toxicity, the key events that initiate or precede the glomerular injury have not yet been identified, and the reason why the renal glomerulus is apparently the major target for MMC-induced renal toxicity is still unknown.

Here we report our findings on the immunohistochemical detection of DT-diaphorase in human kidney.


  Materials and Methods
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Human Tissues
Archival samples of formalin-fixed, paraffin-embedded tissues were supplied by the Institute of Pathology of Southern Switzerland (Locarno, Switzerland). We analyzed 15 bioptic samples of normal human kidney taken from patients who underwent nephrectomy because of kidney carcinoma (hypernephroma). All these patients were chemotherapy-naive.

Methods
We performed an immunohistochemical analysis for detection of DTD on tissue sections using anti-DTD antibodies.

Antibodies and Reagents. Anti-DTD monoclonal antibody (IgG1)-secreting hybridomas (clones A 180 and B 771) were derived from a BALB-c mouse immunized with purified recombinant human DTD protein. All hybridoma cell lines were grown in spinner flasks in RPMI medium containing 50 U/ml penicillin, 50 µg/ml streptomycin, 1% L-glutamine, and 10% fetal bovine serum in 5% CO2 at 37C to a concentration of 106 cells/ml. Hybridoma tissue culture supernatants were prepared by centrifugation at 1800 rpm for 10 min and then stored at –80C.

Before use, supernatants were centrifuged at 14,000 rpm for 5 min. We demonstrated specificity of our proprietary antibody by preabsorbing it with antigen (human recombinant DTD) and showing that immunohistochemical staining was completely blocked. We also performed a Western analysis on tissue extracts to confirm immunohistochemical staining specificity.

Non-human reactive monoclonal mouse antibodies produced in tissue culture, subclass IgG1, were used as negative control reagent (Mouse IgG1 Negative Control Code No. X0931; DAKO, Glostrup, Denmark).

Immunohistochemical Method. Immunohistochemistry was performed on tissue sections (3 µm) cut from archival paraffin blocks. Sections were de-paraffinized in xylene and rehydrated through graded alcohol to running water, then placed in citrate buffer, pH 6.0, and microwaved for two 3-min cycles. Endogenous peroxidase activity was blocked by adding Peroxidase Blocking Agent (DAKO En Vision Kit; Carpinteria, CA). Nonspecific binding was blocked by adding 20% normal rabbit serum. Serial sections of each tissue sample were then incubated with either anti-DTD or control antibodies for 30 min at room temperature. The secondary antibody was added for 30 min (DAKOKIT, labeled Polymer HRP anti-mouse: peroxidase labelled polymer conjugated to goat anti-mouse immunoglobulins). Immunodetection was performed using a substrate–chromogen solution (DAKOKIT, hydrogen peroxide and 3,3'-diaminobenzidine chromogen). Slides were counterstained with hematoxylin, dehydrated through graded alcohols, mounted, and photographed.

Scoring of DTD Immunostaining. The intensity of immunostaining of DTD (brown staining) was visually scored as 0 (negative), +1 (very weak), +2 (weak), +3 (strong), or +4 (very intense), as previously reported for human lung cancers (Siegel et al. 1998 ).


  Results
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

All samples analyzed were suitable for immunohistochemical analysis of DTD expression. There was no immunostaining in control sections when nonspecific antibodies were used.

DTD expression was absent in intertubular stroma (score 0), weak in epithelial cells of proximal convoluted tubules (score +2), strong in epithelial cells of distal convoluted tubules and cortical collecting tubules (score +3), and very strong in glomerular visceral epithelial cells (podocytes) (score +4) of all samples analyzed. Mesangial cells and glomerular parietal epithelial cells did not show any DTD staining (Fig 1A–1C).



View larger version (101K):
[in this window]
[in a new window]
 
Figure 1. Immunoperoxidase staining (DAB) of formalin-fixed, paraffin-embedded human kidney sections using monoclonal antibodies to human DTD. Sections were counterstained with hematoxylin. (A) Weak expression of DTD in proximal convoluted tubules (recognized by a narrow lumen, P), strong expression of DTD in distal convoluted and collecting tubules (recognized by a larger lumen, D). One kidney glomerulus is visible in the middle of the section (G). (B) Higher magnification showing very strong expression of DTD in glomerular visceral epithelial cells (podocytes, brown stained, red arrows). (C) Higher magnification of podocytes (brown-stained, red arrows) covering glomerular capillaries. Glomerular parietal epithelial cells (P) do not express DTD.


  Discussion
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

We report a high expression of DT-diaphorase in human glomerular visceral epithelial cells (podocytes). This implies that DTD-directed compounds, such as MMC, might be selectively bioactivated in podocytes and might thus explain the histological feature of glomerular injury that is central to the pathogenesis of MMC-induced kidney toxicity and hemolytic uremic syndrome. Podocytes are highly differentiated and quiescent cells that play a crucial role in the physiology and pathology of the kidney glomerulus. These cells, which envelop the glomerular capillaries, are an important component of the glomerular filter. The glomerular filtrate must traverse capillary endothelium, basement membrane and the podocyte layer before reaching Bowman's space. Podocytes also produce vascular endothelial growth factor (VEGF), which regulates glomerular endothelial permeability (Kretzler et al. 1998 ). What do we know about renal diseases secondary to podocyte injury? An acquired primary dysregulation of podocytes is described in collapsing idiopathic focal segmental glomerulosclerosis and in HIV-associated nephropathy (Barisoni et al. 1999 , Barisoni et al. 2000 ). A congenitally altered genotype and phenotype of podocytes is also known, such as in congenital nephrotic syndrome, an inherited autosomal recessive disease in which the gene mutated codes for nephrin, a cell surface protein of podocytes (Patrakka et al. 2000 ). Because cells with elevated DTD levels are generally more sensitive to bioreductive antitumor agents such as MMC, a high expression of DTD explains, in theory, a selective toxicity towards podocytes of DTD-bioactivated compounds. There are two clinically distinct patterns of MMC-induced renal damage (Hanna et al. 1981 ), an acute and often rapidly fatal glomerular toxicity associated with microangiopathic hemolytic anemia and thrombocytopenia (cancer-associated hemolytic uremic syndrome; C-HUS), and a more chronic and progressive renal toxicity not associated with other C-HUS features. Both types show that an injury to the glomerular filter is central to the pathogenesis of renal damage (Hanna et al. 1981 ; Verwey et al. 1984 ; Jain and Seymour 1987 ). It is assumed that this precedes platelet activation and consumption in C-HUS. Histology shows typical renovascular damage characterized by necrosis and sclerosis of glomeruli, as well as mesangial interdeposition with double contouring of glomerular basement membranes and large atypical endothelial cell nuclei (Liu et al. 1971 ; Hanna et al. 1981 ; Verwey et al. 1984 ; Cantrell et al. 1985 ; Price et al. 1985 ; Sheldon and Slaughter 1986 ). These histological changes are similar to those observed in other glomerulopathies secondary to acquired or congenital podocyte dysfunction. It therefore seems reasonable to postulate that a high expression of DTD in human podocytes could be responsible for MMC-induced renal toxicity.

If the high expression of DT-diaphorase in these cells is the key element in the pathogenesis of MMC-induced toxicity, other questions remain unanswered. Why is the risk for development of C-HUS after treatment with MMC between 4% and 15% and not higher? What is it that protects more than 85% of patients against this potentially lethal side effect? We propose the following mechanisms that might explain this individual susceptibility to MMC-related renal toxicity. (a) DT-diaphorase can be induced by a wide variety of compounds, including many dietary substances (Benson et al. 1980 ; O'Dwyer et al. 1996 ; Begleiter et al. 1997 ; Wang et al. 1999 ). For example, rapid induction of this enzyme has been demonstrated in subjects who regularly ingest coffee or broccoli (Sreerama et al. 1995 ). Moreover, in a previous study the major determinant of the variability of human lung DT-diaphorase was the cigarette-smoking history of the patient and the alcohol intake (Schlager and Powis 1990 ). Dietary or comportmental habits might increase the individual expression of DT-diaphorase enough to predispose to MMC-related toxicity. (b) Previous results indicate that DT-diaphorase activity is required for effective cytotoxicity of quinone-containing agents in human carcinoma cell lines (Lee et al. 1993 ; Sun and Ross 1996 ; Belcourt et al. 1998 ). However, cytogenetic heterogeneity within the tumor cell population and the various environmental factors that impact on bioreductive enzyme function, including pH and oxygen tension, may subvert this approach (Siegel et al. 1990 ; Begleiter et al. 1992 ; Begleiter and Leith 1993 ; Saeki et al. 1995 ). Individual variations in oxygen tension and pH (chronic lung diseases, metabolic or respiratory acid–basic status dysregulations) could play a role in modulating MMC cell metabolism. Kidney capillaries are located in a physiologically strategic pathway of acid–basic homeostasis, and this could influence DTD sensitivity to MMC. (c) DT-diaphorase is known to share two different functions, a bioactivating function that is exploited in antitumor activity and a more physiological phase II detoxifying function. The high expression of DT-diaphorase in podocytes could be related to a physiological detoxifying role, protecting these cells from potentially cytotoxic or mutagen xenobiotics filtered in the glomerular urinary space from the bloodstream. A lack of this enzyme in podocytes would therefore render these cells more sensitive to the toxic effect of physiologically occurring or pharmacological bioreductive compounds. This "fragile" podocyte will be particularly sensitive to the toxic effect of DTD-directed anticancer compounds. A polymorphism of the gene encoding DT-diaphorase has been described (Traver et al. 1997 ). This mutation (a C-to-T transition at base pair 609 coding for a proline to serine substitution) causes a loss of enzyme activity (Ross et al. 1996 ; Siegel et al. 1999 ) and resistance to anticancer agents that require reductive activation (Lambert et al. 1998 ). Individuals homozygous for this change (T/T) have no detectable DT-diaphorase activity. Previous studies indicate a significant ethnic variation in the occurrence of this point mutation (Edwards et al. 1983 ). A 4%–6% range of individuals homozygous for the mutation has been reported for the general population of the UK and among whites and African–Americans (Larson et al. 1999 ), and a higher incidence for Hispanics and Asians (Wiencke et al. 1997 ; Chen et al. 1999 ). An individual genetic variation in DT-diaphorase activity could at least partially explain the variation in susceptibility to MMC. Moreover, even if the two-electron pathway catalyzed by DT-diaphorase and unimpeded by molecular oxygen is probably the critical pathway for MMC antitumor activity, through a one-electron pathway catalyzed by NADPH-dependent cytochrome P450 reductase and impeded by molecular oxygen, semiquinone free radical intermediates are formed that may participate in MMC-induced toxicity (Bachur 1978 ; Lind et al. 1982 ; Siegel et al. 1990 ; Niedermeyer et al. 1999 ). In individuals lacking DT-diaphorase activity because they are homozygous for the point mutation, MMC metabolism preferentially follows the one-electron pathway catalyzed by the cytochrome P450 reductase, leading to minor antitumor activity but also to increased production of free radicals potentially responsible for cytotoxicity. A previous study suggests that DT-diaphorase can reduce MMC to potent cytotoxic species under aerobic conditions, and this activity predominates over the one-electron-reducing enzymes even in hypoxic conditions. In the absence of DT-diaphorase activity because of the point mutation in the NQO1 gene, MMC is reduced in hypoxic conditions by one-electron-reducing enzymes (Plumb and Workman 1994 ). Because of the similar range of incidence reported for individuals homozygous for the NQO1 gene point mutation and for C-HUS and MMC-induced renal toxicity, the DTD-independent one-electron metabolism of MMC could be the critical pathway leading to renal toxicity, affecting only DTD-deficient individuals. Until now, no studies have focused on the possible relationship between the NQO1 gene mutation and the incidence of MMC-induced C-HUS.

We postulate that genetic, dietary, and environmental cell factors may be responsible for the individualism of susceptibility to DTD-directed anticancer agents. We also propose that MMC-induced hemo-lytic uremic syndrome and kidney toxicity could be related to the point mutation in the NQO1 gene, encoding an inactive protein. This report represents an attempt to explain the selective toxicity of quinones on kidney glomeruli, and proposes exciting new fields for further research.


  Acknowledgments

Francesco Zappa is supported by an ESMO (European Society for Medical Oncology) grant.

Anti-DTD antibodies were a generous gift from Prof David Ross (Department of Pharmaceutical Sciences, School of Pharmacy and Cancer Center, University of Colorado Health Sciences Center; Denver, Colorado).

Received for publication February 27, 2002; accepted October 9, 2002.


  Literature Cited
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Bachur N (1978) General mechanism for the biological activation of quinone anticancer agents to free radicals. Proc In Congr Chemother 11:1124

Barisoni L, Kriz W, Mundel P, D'Agati V (1999) The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 10:51-61[Abstract/Free Full Text]

Barisoni L, Mokrzycki M, Sablay L, Nagata M, Yamase H, Mundel P (2000) Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 58:137-143[Medline]

Beall HD, Murphy AM, Siegel D, Hargreaves RHJ, Butler J, Ross D (1995) NAD(P)H: quinone oxidoreductase (DT-diaphorase) as a target for bioreductive anti-tumour quinones; quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 48:499-504[Abstract]

Begleiter A, Leith MK (1993) Role of NAD(P)H(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under acidic conditions. Mol Pharmacol 44:210-215[Abstract]

Begleiter A, Leith MK, Curphey TJ, Doherty GP (1997) Induction of DT-diaphorase in cancer chemoprevention and chemotherapy. Oncol Res 9:371-382[Medline]

Begleiter A, Robotham E, Leith MK (1992) Role of NAD(P)H (quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia. Mol Pharmacol 41:677-682[Abstract]

Belcourt MF, Hodnick WF, Rockwell S, Sartorelli AC (1998) Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH: cytochrome C (P-450) reductase and DT-diaphorase. Adv Enzyme Regul 38:111-133[Medline]

Belinsky M, Jaiswal AK (1993) NAD(P)H: quinone oxidoreductase (DT-diaphorase) expression in normal and tumor tissues. Cancer Metast Rev 12:103-117[Medline]

Benson AM, Hunkler MJ, Talalay P (1980) Increase of NAD(P)H: quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc Natl Acad Sci USA 77:5216-5220[Abstract]

Cantrell JE, Phillips TM, Schein PS (1985) Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol 3:723-734[Abstract]

Chen H, Lum A, Seifried A, Wilkens LR, Le Marchand L (1999) Association of the NAD(P)H: quinone oxidoreductase 609 C to T polymorphism with a decreased lung cancer risk. Cancer Res 59:3045-3048[Abstract/Free Full Text]

Chesis PL, Levin DE, Smith MT, Ernster L, Ames BN (1984) Mutagenicity of quinones: pathways of metabolic activation and detoxification. Proc Natl Acad Sci USA 81:1696-1700[Abstract]

Cresteil T, Jaiswal AK (1991) High levels of expression of the NAD(P)H: quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 42:1021-1027[Medline]

Edwards YH, Hopkinson DA, Carritt B (1983) A genetic characterization of the human diaphorase-4 deficiency. Ann Hum Genet 47:97-105[Medline]

Hanna WT, Krauss S, Regester RF, Murphy WM (1981) Renal disease after mitomycin C therapy. Cancer 48:2583-2588[Medline]

Jain S, Seymour AE (1987) Mitomycin C associated hemolytic uremic syndrome. Pathology 19:58-61[Medline]

Kretzler M, Schroppel B, Merkle M, Huber S, Mundel P, Horster M, Schlondorff D (1998) Detection of multiple vascular endothelial growth factor splice isoforms in single glomerular podocytes. Kidney Int Suppl 67:159-161

Lambert PA, Kang Y, Greaves B, Perry RR (1998) The importance of DTD in mitomycin C resistance in human colon cancer cell lines. J Surg Res 80:177-181[Medline]

Larson RA, Wang Y, Banerjee M, Wiemels J, Hartford C, Beau MM, Smith MT (1999) Prevalence of the inactivating 609 C to T polymorphism in the NAD(P)H: quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 94:803-807[Abstract/Free Full Text]

Lee JH, Naito M, Nakajima M, Tsuruo T (1993) Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells. Cancer Chemother Pharmacol 33:215-220[Medline]

Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, Arbus M et al. (1989) Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 7:781-789[Abstract]

Lind C, Hochstein P, Ernster L (1982) DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. Arch Biochem Biophys 216:178-185[Medline]

Liu K, Mittelman A, Sproul EE, Elias EG (1971) Renal toxicity in man treated with mitomycin C. Cancer 28:1314-1320[Medline]

Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, Bunn PA et al. (1992) Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma; relationship to the response of lung tumour xenografts to mitomycin C. Cancer Res 52:4752-4757[Abstract]

Mikami K, Naito M, Tomida A (1996) DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res 56:2823-2826[Abstract]

Niedermeyer J, Fabel H, Carsten B, Lipp HP (1999) Pulmonary toxicity of chemotherapeutic agents. In Lipp HP, ed. Anticancer Drug Toxicity. New York, Basel, Marcel Dekker, 455-470

O'Dwyer PJ, Szarka CE, Yao KS, Halbherr TC, Pfeiffer GR, Green F, Gallo JM et al. (1996) Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest 98:1210-1217[Abstract/Free Full Text]

Patrakka J, Kestila M, Wartiovaara J, Ruotsalainen V, Tissari P, Lenkkeri U, Mannikko M et al. (2000) Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in Finnish patients. Kidney Int 58:972-980[Medline]

Plumb JA, Workman P (1994) Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 56:134-139[Medline]

Price TM, Murgo AJ, Keveney JJ, Miller–Hardy D, Kasprisin DO (1985) Renal failure and hemolytic anemia associated with mitomycin C. Cancer 55:51-56[Medline]

Ross D, Beall H, Traver R, Siegel D, Phillips RM, Gibson NW (1994) Bioactivation of quinones by DT-diaphorase, molecular, biochemical and chemical studies. Oncol Res 6:493-500[Medline]

Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT, Gibson NW (1993) DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metast Rev 12:83-101[Medline]

Ross D, Traver RD, Siegel D (1996) A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): relationship of homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer 74:995-996[Medline]

Saeki S, Nishiyama M, Toge T (1995) DT-diaphorase as a target enzyme for biochemical modulation of mitomycin C. Hiroshima J Med Sci 44:55-63[Medline]

Sartorelli AC (1986) The role of mitomycin antibiotics in the chemotherapy of solid tumours. Biochem Pharmacol 35:67-69[Medline]

Schlager JJ, Powis G (1990) Cytosolic NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 45:403-409[Medline]

Sheldon R, Slaughter D (1986) A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 58:1428-1436[Medline]

Siegel D, Franklin WA, Ross D (1998) Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 4:2065-2070[Abstract]

Siegel D, Gibson NW, Preusch PC, Ross D (1990) Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50:7483-7489[Abstract]

Siegel D, McGuiness SM, Winski SL, Ross D (1999) Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H: quinone oxidoreductase 1. Pharmacogenetics 9:113-121[Medline]

Smitskamp–Wilms E, Giaccone G, Pinedo HM, van der Laan BFAM, Peters GJ (1995) DT-diaphorase activity in normal and neoplastic human tissues: an indicator for sensitivity to bioreductive agents. Br J Cancer 72:917-921[Medline]

Sreerama L, Hedge MW, Sladek NE (1995) Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione S-transferases, and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli. Clin Cancer Res 1:1153-1163[Abstract]

Sun X, Ross D (1996) Quinone induced apoptosis in human colon adenocarcinoma cells via DT-diaphorase mediated bioactivation. Chem Biol Interact 100:267-276[Medline]

Traver RD, Siegel D, Beall HD, Phillips RM, Ross D (1997) Characterisation of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br J Cancer 75:69-75[Medline]

Valavaara R, Nordman E (1985) Renal complications of mitomycin C therapy with special reference to the total dose. Cancer 55:47-50[Medline]

Verwey J, Boven E, Van Der Meulen J, Pinedo HM (1984) Recovery from mitomycin C-induced hemolytic uremic syndrome. Cancer 54:2878-2881[Medline]

Verwey J, de Vries J, Pinedo HM (1987) Mitomycin C-induced renal toxicity, a dose-dependent side effect? Eur J Cancer Clin Oncol 23:195-199[Medline]

Wakaki S, Marumo H, Tamioka K, Shimizu G, Kato E, Kamada H, Kudo S et al. (1958) Antibiotics and chemotherapy. J Clin Exp Stud 8:228

Wang X, Doherty GP, Leith MK, Begleiter A (1999) Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase. Br J Cancer 80:1223-1230[Medline]

Wiencke JK, Spitz MR, McMillan A, Kelsey KT (1997) Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 6:87-92[Abstract]

Workman P (1994) Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 6:461-475[Medline]

Workman P, Stratford IJ (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metast Rev 12:73-82[Medline]